Premium
Clinical kinetics of intact cisplatin and some related species
Author(s) -
Himmelstein Kenneth J,
Patton Thomas F,
Belt Robert J,
Taylor Sarah,
Repta A J,
Sternson Larry A
Publication year - 1981
Publication title -
clinical pharmacology and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.941
H-Index - 188
eISSN - 1532-6535
pISSN - 0009-9236
DOI - 10.1038/clpt.1981.91
Subject(s) - cisplatin , mannitol , platinum , chemistry , pharmacokinetics , kinetics , pharmacology , blood plasma , plasma concentration , medicine , endocrinology , chemotherapy , biochemistry , physics , quantum mechanics , catalysis
Plasma concentrations of cisplatin, total platinum, and total filterable platinum were monitored in 24 patients after either 50 or 100 mg/m 2 of cisplatin by rapid intravenous injection. Half the patients at each dose were pre treated with mannitol. Total platinum levels declined in a triphasic fashion with a terminal half‐life (t½) ≥24 hr. Both total filterable platinum and cisplatin levels declined in a monophasic manner and exhibited t½s of 0.3 to 0.5 hr. The ratio of cisplatin to total filterable platinum in plasma remained constant (0.6 to 0.8) over the time period (2 hr) during which they could be detected, while the ratio of the plasma levels of cisplatin to total platinum decreased continuously from ≈0.5 at 5 min to approximately 0.10 at 2 hr. Larger doses of cisplatin resulted in higher plasma levels of all three species monitored, and although the increases appeared somewhat less than proportional to dose, terminal plasma slopes were not dose dependent. Neither mannitol nor dose had an effect on the various species ratios, nor did mannitol appear to affect either plasma levels or terminal plasma decline. Clinical Pharmacology and Therapeutics (1981) 29, 658–664; doi: 10.1038/clpt.1981.91